Fuente: "milk OR dairy products" J Allergy Clin Immunol Pract. 2026 Mar 7:S2213-2198(26)00185-6. doi: 10.1016/j.jaip.2026.02.033. Online ahead of print.ABSTRACTBACKGROUND: Although omalizumab is now approved for the treatment of food allergy (FA), little is known about its use in the clinical setting.OBJECTIVE: To examine the outcome of oral food challenges (OFCs) after treatment with omalizumab.METHODS: We conducted a retrospective chart review of clinic patients who underwent OFCs after treatment with omalizumab, including cumulative tolerated doses and all adverse events.RESULTS: 51 patients (45% female; median age 9 [range 1-23] years; median total IgE 512 [IQR: 285, 1080] IU/mL) underwent 73 OFCs, with milk (n=27), egg (n=23), and wheat (n=9) accounting for 81% of the OFCs. A reaction history was documented for 95% and all challenged foods had a positive allergen-specific IgE (median 34 [IQR: 12, >100] kUA/L). OFCs were performed at a median of 7 months (range: 4-14) after starting omalizumab. Among OFCs to any food with a goal dose ≥6000 mg (n=56), 89% successfully consumed ≥1000 mg, 86% ≥2000 mg, 75% ≥4000 mg, and 66% ≥6000 mg. Allergic reactions occurred in 45% (n=33) of all OFCs with 21 treated with antihistamines and 2 treated with epinephrine. Dietary introduction of allergenic foods was permitted following 92% of OFCs. Omalizumab treatment response was associated with higher baseline total IgE, q2 versus q4 week dosing, higher total omalizumab dose per 4-weeks per weight, and lower allergen-specific IgE to total IgE ratio.CONCLUSION: Omalizumab can be effectively used for the treatment of FA in the clinical setting and may enable the introduction of allergenic foods into the diet for most patients.PMID:41802568 | DOI:10.1016/j.jaip.2026.02.033